Finance

Lists
Why is NMRA down 9.11%?
Dive Deeper
NMRA:NASDAQ
Neumora Therapeutics Inc
$ 0.50
-9.11%
(-0.050) 1D
$ 0.50
+0.02% (+0.000100)
After hours
Closed: 10-р сарын 2, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NMRA...
Open
$ 0.56
High
$ 0.56
Low
$ 0.48
Mkt. cap
93.93 сая
Avg. vol.
1.48 сая
Volume
2.69 сая
52-wk high
$ 3.65
52-wk low
$ 0.48
EPS
-$ 1.23
Beta
2.95
Shares outstanding
187.90 сая
No. of employees
63
Open
$ 0.56
High
$ 0.56
Low
$ 0.48
Mkt. cap
93.93 сая
Avg. vol.
1.48 сая
Volume
2.69 сая
52-wk high
$ 3.65
52-wk low
$ 0.48
EPS
-$ 1.23
Beta
2.95
Shares outstanding
187.90 сая
No. of employees
63
News stories
From web sources and news partners
About Neumora Therapeutics Inc
CEO-
Employees63
Founded2019
HeadquartersWatertown, Массачусеттс, Америкийн Нэгдсэн Улс
SectorPharmaceutical industry
Websiteneumoratx.com
Analyst ratings
Based on 5 analysts giving stock ratings to NMRA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NMRA in the last 3 months.
Highest
Current $ 0.50
$ 7.00 (+1,300.28%)
Average
$ 5.25 (+950.21%)
Lowest
$ 4.00 (+700.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$ 7.00
+1,300.3%
08/24/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$ 4.00
+700.2%
08/17/2026
Ami Fadia
Needham
Buy
Reiterated
$ 5.00
+900.2%
08/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$ 5.00
+900.2%
08/14/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
05/26/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$ 3.00
+500.1%
05/12/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$ 14.00
+2,700.6%
05/07/2026
Last report
2026 оны 8-р сарын 14
Fiscal period
Q2 2026
EPS / Est. (USD)
-$ 0.23 / -$ 0.24
+5.34%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
40.52 сая
44.67 сая
38.60 сая
29.28 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.18 сая
13.81 сая
14.27 сая
12.91 сая
Operating expense
52.70 сая
58.48 сая
52.86 сая
42.19 сая
Total operating expenses
52.70 сая
58.48 сая
52.86 сая
42.19 сая
Operating income
-52.70 сая
-58.48 сая
-52.86 сая
-42.19 сая
Other non operating income
7.00 мян
-269.00 мян
59.00 мян
-7.00 мян
EBT including unusual items
-56.76 сая
-59.45 сая
-53.43 сая
-43.08 сая
EBT excluding unusual items
-51.76 сая
-59.45 сая
-53.43 сая
-43.08 сая
Income tax expense
-
-
30.00 мян
-
Effective tax rate
-
-
-0.06%
-
Other operating expenses
-
-
-
-
Net income
-56.76 сая
-59.45 сая
-53.46 сая
-43.08 сая
Net profit margin
-
-
-
-
Earnings per share
-0.35
-0.35
-0.30
-0.23
Interest and investment income
1.68 сая
1.34 сая
1.23 сая
935.00 мян
Interest expense
-747.00 мян
-2.04 сая
-1.85 сая
-1.82 сая
Net interest expenses
938.00 мян
-701.00 мян
-623.00 мян
-885.00 мян
Depreciation and amortization charges
-
-
-
-
EBITDA
-52.68 сая
-58.47 сая
-52.86 сая
-42.18 сая
Gain or loss from assets sale
-62.00 мян
264.00 мян
-71.00 мян
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс